The work of Oshima et al. is of particular interest for finding no major differences between BCP and T-ALL except for the activating mutations in the NRAS and KRAS oncogenes, which were primarily early events in T-ALL and more heterogeneously distributed in B-precursor ALL [93]. The gene discussed is NRAS; the disease is acute lymphoblastic leukemia.